State of Wyoming Purchases Shares of 114,273 CureVac N.V. $CVAC

State of Wyoming purchased a new stake in CureVac N.V. (NASDAQ:CVAC) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 114,273 shares of the company’s stock, valued at approximately $317,000.

Several other large investors have also made changes to their positions in CVAC. GSA Capital Partners LLP acquired a new position in shares of CureVac during the 1st quarter worth approximately $853,000. BNP Paribas Financial Markets acquired a new position in shares of CureVac during the 4th quarter worth approximately $585,000. Two Sigma Investments LP acquired a new position in shares of CureVac during the 4th quarter worth approximately $391,000. Alyeska Investment Group L.P. raised its stake in shares of CureVac by 25.0% during the 4th quarter. Alyeska Investment Group L.P. now owns 500,000 shares of the company’s stock worth $1,705,000 after buying an additional 100,000 shares during the period. Finally, Nuveen LLC acquired a new position in shares of CureVac during the 1st quarter worth approximately $232,000. 17.26% of the stock is owned by institutional investors and hedge funds.

CureVac Price Performance

Shares of CVAC opened at $5.37 on Tuesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.16 and a current ratio of 6.17. CureVac N.V. has a one year low of $2.37 and a one year high of $5.72. The stock has a market capitalization of $1.20 billion, a price-to-earnings ratio of 5.59 and a beta of 2.53. The stock has a 50 day moving average price of $5.43 and a 200 day moving average price of $4.23.

CureVac (NASDAQ:CVAC) last issued its quarterly earnings results on Thursday, August 21st. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.15). CureVac had a return on equity of 29.57% and a net margin of 38.21%.The firm had revenue of $1.41 million for the quarter, compared to analysts’ expectations of $4.27 million. Equities research analysts forecast that CureVac N.V. will post 0.72 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on CVAC shares. Citizens Jmp downgraded CureVac from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 12th. JMP Securities reaffirmed a “market outperform” rating and set a $10.00 target price on shares of CureVac in a research note on Wednesday, May 28th. Citigroup downgraded CureVac to a “market perform” rating in a research note on Thursday, June 12th. Jefferies Financial Group reaffirmed a “hold” rating and set a $5.00 target price (down from $7.00) on shares of CureVac in a research note on Friday, June 13th. Finally, UBS Group cut CureVac from a “strong-buy” rating to a “neutral” rating and dropped their price target for the stock from $12.00 to $5.50 in a research report on Thursday, June 26th. One equities research analyst has rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $6.83.

CureVac Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.